GBA Presents: House of Gummy-!

DTST->$2.76----> $3.05 My day is done> :cool:

2 FOR 2:caution:

Oh man poor Van he goes on vacation and he is always overwhelmed by the number of good ideas I have; today I had to take my car in and so I could not do a ton of work i just gave out two names and... oh well That's stonedinvesting!


Data Storage Corporation (DTST)
NasdaqCM - NasdaqCM Real Time Price.

3.0519+0.5019 (+19.68%)<----------:thumbsup:
As of 03:27PM EDT.
 
CET said:
Look at a long term chart. It is a disaster with reverse splits. There is a big bounce the last few days on regaining nasdaq compliance with the most recent reverse split.
More...




Ahhh reverse split thank you sir! I don't have to beat myself up it didn't go from $2-$5!!!

It was a shock to see it at $5 yes troubled co... I forget the original premise they were helping to stop smoking? Or stop vaping.
 
The stock is to expensive and I don't love this option.

Barbie movie is going to drive sales at FIVE <--------


FIVE Aug 2023 210.000 call
OPR - OPR Delayed Price. Currency in USD
Follow
3.0000-0.4000 (-11.76%)<-- not so great discount
As of 03:47PM EDT.
 
The Jeep comes home tomorrow. I drive her tomorrow.
We go to the wine store together.
Me, The Jeep and the wife.

I like to drive distances that in a pinch I could walk home from.
1987 comes alive and then some.
Tomorrow we drive. Till' the end sun.
The jeep and I and the wife.
 
It will be hard to top the last few Weekend Reviews- Last week we stumbled onto the #1 gainer---

Rocket soars to top industrial gainer of week, Joby lands among losers

This week my mind is blank. We already shot our Barbie load.. I should of held that back...

The only thing that comes to mind this morning is Bluebird.>

BLUE has a perfect double bottom at $3. >

Now we have to ask ourselves how did we get here? This was an $8 stk. So some research is needed... What went wrong around Feb 10.

Why has the stk been down so long? And what has changed?

bluebird bio gains as BofA upgrades citing FDA nod for new gene therapy

bluebird bio gains on FDA priority review for new gene therapy

I believe it actually was a competitor either CRSPR or NTLA that had some good news about their gene therapy that rubbed off on Blue..

Barclays ups bluebird rating to overweight, citing sickle cell opportunity.

GBA STOCK OF THE WEEK--
BLUEbluebird bio, Inc.

$4.05 +0.54(+15.38%)

https://seekingalpha.com/symbol/BLUE/charting?compare=BLUE&interval=6M&metric=priceReturn



 
You must log in or register to reply here.
Back
Top